Trailer and series launch in January 2026; social-first distribution to be followed with a proprietary app experience LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) — Native, a clean beauty and personal care brand, P&G Studios, a division of Procter & Gamble, and dentsu Entertainment, a division of dentsu, today announced the first brand co-produced feature-length […]
Asean
Zoom Leads A Workplace Revolution
Major new brand campaign developed with Colin Jost’s No Notes Productions lampoons bad tech and champions the employees who suffer for it SAN JOSE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Today, on behalf of employees everywhere, Zoom announced the launch of a major brand campaign developed with Colin Jost’s No Notes Productions lampooning the […]
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy
RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled automation, and cloud-native platforms. New […]
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (“EBC”) has been named Best Broker for Execution at the Professional Trader Awards 2025, […]
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time […]